Blueprint Medicines Corporation (0HOJ.L)
USD 83.55
(4.15%)
USD 83.55
(4.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -474.61 Million USD | 11.7% |
| 2022 | -515.41 Million USD | 16.27% |
| 2021 | -628.29 Million USD | -307.96% |
| 2020 | 308.7 Million USD | 185.44% |
| 2019 | -356.06 Million USD | -52.74% |
| 2018 | -242.78 Million USD | -59.95% |
| 2017 | -149.66 Million USD | -105.34% |
| 2016 | -70.44 Million USD | -38.32% |
| 2015 | -51.12 Million USD | -32.81% |
| 2014 | -39.11 Million USD | -93.41% |
| 2013 | -20.49 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -33.37 Million USD | -13.23% |
| 2024 Q1 | -74.01 Million USD | 28.54% |
| 2024 Q2 | -39.42 Million USD | 60.18% |
| 2023 Q4 | -103.57 Million USD | 19.69% |
| 2023 FY | - USD | 11.7% |
| 2023 Q1 | -123.22 Million USD | 17.74% |
| 2023 Q2 | -127.98 Million USD | -3.86% |
| 2023 Q3 | -128.98 Million USD | -0.78% |
| 2022 Q1 | -104.17 Million USD | 67.05% |
| 2022 FY | - USD | 16.27% |
| 2022 Q2 | -156.16 Million USD | -49.91% |
| 2022 Q4 | -149.79 Million USD | -22.13% |
| 2022 Q3 | -122.65 Million USD | 21.46% |
| 2021 Q4 | -316.13 Million USD | -173.76% |
| 2021 Q1 | -98.63 Million USD | -14.73% |
| 2021 Q2 | -106.91 Million USD | -8.4% |
| 2021 Q3 | -115.48 Million USD | -8.01% |
| 2021 FY | - USD | -307.96% |
| 2020 FY | - USD | 185.44% |
| 2020 Q4 | -85.96 Million USD | -113.54% |
| 2020 Q3 | 635.01 Million USD | 607.86% |
| 2020 Q2 | -125.03 Million USD | -11.55% |
| 2020 Q1 | -112.08 Million USD | -61.56% |
| 2019 Q2 | -97.16 Million USD | -14.07% |
| 2019 Q3 | -91.66 Million USD | 5.67% |
| 2019 Q4 | -69.37 Million USD | 24.31% |
| 2019 FY | - USD | -52.74% |
| 2019 Q1 | -85.18 Million USD | -6.06% |
| 2018 Q1 | -55.73 Million USD | -13.78% |
| 2018 Q2 | -25.89 Million USD | 53.55% |
| 2018 Q3 | -71.54 Million USD | -176.32% |
| 2018 Q4 | -80.31 Million USD | -12.26% |
| 2018 FY | - USD | -59.95% |
| 2017 Q3 | -37.26 Million USD | -13.05% |
| 2017 Q2 | -32.96 Million USD | -19.82% |
| 2017 Q1 | -27.5 Million USD | -29.92% |
| 2017 FY | - USD | -105.34% |
| 2017 Q4 | -48.98 Million USD | -31.47% |
| 2016 Q4 | -21.17 Million USD | -29.75% |
| 2016 Q3 | -16.31 Million USD | 11.17% |
| 2016 Q2 | -18.36 Million USD | -22.64% |
| 2016 FY | - USD | -38.32% |
| 2016 Q1 | -14.97 Million USD | 2.83% |
| 2015 Q3 | -12.26 Million USD | 2.64% |
| 2015 FY | - USD | -32.81% |
| 2015 Q2 | -12.59 Million USD | -12.71% |
| 2015 Q4 | -15.41 Million USD | -25.66% |
| 2015 Q1 | -11.17 Million USD | 20.79% |
| 2014 FY | - USD | -93.41% |
| 2014 Q1 | -6.8 Million USD | 0.0% |
| 2014 Q3 | -10.24 Million USD | -27.06% |
| 2014 Q4 | -14.11 Million USD | -37.8% |
| 2014 Q2 | -8.05 Million USD | -18.5% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 104.395% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -37.384% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -78.428% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -303.41% |
| uniQure N.V. | -253.1 Million USD | -87.52% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -415.44% |
| bluebird bio, Inc. | -167.16 Million USD | -183.925% |
| Imunon, Inc. | -20.78 Million USD | -2183.735% |
| Dynavax Technologies Corporation | 9.66 Million USD | 5010.118% |
| Editas Medicine, Inc. | -163.11 Million USD | -190.964% |
| Illumina, Inc. | -608 Million USD | 21.939% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | -5.701% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 114.577% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 140.773% |
| Myriad Genetics, Inc. | -67.8 Million USD | -600.018% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 214.062% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -8.064% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 583.007% |
| Verastem, Inc. | -83.16 Million USD | -470.68% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 95.792% |
| Waters Corporation | 1.02 Billion USD | 146.428% |
| Biogen Inc. | 2.37 Billion USD | 119.967% |
| Nektar Therapeutics | -243.1 Million USD | -95.228% |
| Perrigo Company plc | 646.2 Million USD | 173.447% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -968.063% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -357.272% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1172.998% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 252.961% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -442.867% |
| Evolus, Inc. | -41.81 Million USD | -1035.164% |
| Adicet Bio, Inc. | -136.53 Million USD | -247.612% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -439.424% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 110.197% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -216.18% |
| FibroGen, Inc. | -261.4 Million USD | -81.562% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 128.301% |
| OPKO Health, Inc. | -65.51 Million USD | -624.422% |
| Homology Medicines, Inc. | -47.75 Million USD | -893.827% |
| Geron Corporation | -174.78 Million USD | -171.545% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -108.053% |
| Exelixis, Inc. | 196.6 Million USD | 341.408% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -370.719% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -751.23% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 6.262% |
| Zoetis Inc. | 3.68 Billion USD | 112.88% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -110.947% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -838.488% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 110.306% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1215.371% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -106.344% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 538.141% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 205.015% |
| Insmed Incorporated | -654.73 Million USD | 27.511% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1918.437% |
| Incyte Corporation | 919.42 Million USD | 151.62% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 6.073% |